| scholarly article | Q13442814 |
| P2093 | author name string | J Braun | |
| J Sieper | |||
| P2860 | cites work | Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial | Q28214774 |
| A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index | Q28299001 | ||
| Commented glossary for rheumatic spinal diseases, based on pathology | Q33578214 | ||
| Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis | Q33860755 | ||
| The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy | Q34016674 | ||
| Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria | Q34055060 | ||
| Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiences | Q34071316 | ||
| Pierre Marie. Pioneer investigator in ankylosing spondylitis. | Q34307503 | ||
| Entheses and enthesitis: a histopathologic review and relevance to spondyloarthritides | Q34368833 | ||
| Treatment of spondyloarthropathies. Recent advances and prospects in 2001. | Q34504801 | ||
| New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy. | Q34560574 | ||
| Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study | Q35549397 | ||
| Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha | Q35550729 | ||
| Therapeutic aspects of spondyloarthropathies -- a review | Q37879833 | ||
| The spondylarthropathies: classification and diagnosis. Do we need new terminologies? | Q40826149 | ||
| Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab | Q42628068 | ||
| A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis | Q43937874 | ||
| Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study | Q45335425 | ||
| Ankylosing spondylitis 1992: from Connor to transgenes | Q47257550 | ||
| Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. | Q50913336 | ||
| Meta-analysis of sulfasalazine in ankylosing spondylitis | Q68165269 | ||
| Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients | Q72044965 | ||
| Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study | Q72231863 | ||
| Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? | Q73069514 | ||
| Oral quinine in ankylosing spondylitis: a randomized placebo controlled double blind crossover trial | Q74214754 | ||
| On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany, | Q74319712 | ||
| Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study | Q74602875 | ||
| Spondylarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation | Q77936271 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Germany | Q183 |
| ankylosing spondylitis | Q52849 | ||
| workshop | Q27556165 | ||
| P304 | page(s) | iii61-7 | |
| P577 | publication date | 2002-12-01 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Building consensus on nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18-19 January 2002 | |
| P478 | volume | 61 Suppl 3 |
| Q49119264 | A survey of European and Canadian rheumatologists regarding the treatment of patients with ankylosing spondylitis and extra-articular manifestations |
| Q89099228 | Association of rs11209032 and rs1004819 Polymorphisms in Interleukin-23 Receptor Gene With Ankylosing Spondylitis |
| Q56974069 | Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors |
| Q24617746 | Classification criteria for spondyloarthropathies |
| Q37203396 | Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease |
| Q36830824 | Enteropathic spondyloarthritis: from diagnosis to treatment. |
| Q64238117 | Musculoskeletal Clinical and Imaging Manifestations in Inflammatory Bowel Diseases |
| Q33783951 | Reporting of patient-perceived impact of rheumatoid arthritis and axial spondyloarthritis over 10 years: a systematic literature review |
| Q36040093 | Seronegative spondyloarthropathies: to lump or split? |
| Q35210198 | Spondyloarthropathy for practicing rheumatologists: diagnosis, indication for disease-controlling antirheumatic therapy, and evaluation of the response |
| Q89928065 | The occurrence of sacroiliitis in HLA-B*35-positive patients with undifferentiated spondyloarthritis. A cross sectional MRI study |
| Q53517753 | [Imaging in ankylosing spondylitis]. |
Search more.